Marcum Wealth LLC Sells 40 Shares of Stryker Co. (NYSE:SYK)

Marcum Wealth LLC decreased its stake in shares of Stryker Co. (NYSE:SYK) by 4.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 872 shares of the medical technology company’s stock after selling 40 shares during the quarter. Marcum Wealth LLC’s holdings in Stryker were worth $314,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dunhill Financial LLC boosted its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Centennial Bank AR boosted its stake in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after purchasing an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new position in Stryker in the 3rd quarter valued at $36,000. HBW Advisory Services LLC bought a new position in Stryker during the 3rd quarter worth $42,000. Finally, Hara Capital LLC acquired a new stake in shares of Stryker during the third quarter worth $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 5.90% of the company’s stock.

Stryker Trading Up 0.5 %

Shares of Stryker stock opened at $362.68 on Wednesday. The firm’s 50 day moving average is $375.13 and its 200 day moving average is $358.25. The firm has a market capitalization of $138.26 billion, a PE ratio of 38.87, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.93%. The ex-dividend date of this dividend is Tuesday, December 31st. Stryker’s dividend payout ratio is 36.01%.

Analysts Set New Price Targets

SYK has been the topic of several research reports. Truist Financial upped their price target on shares of Stryker from $380.00 to $409.00 and gave the company a “hold” rating in a research note on Wednesday, December 18th. Canaccord Genuity Group increased their target price on shares of Stryker from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Thursday, January 9th. Citigroup boosted their price target on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, UBS Group raised their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.